Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Amortization - Deferred Charges Cost of Revenue Depreciation & Amortization (IS)EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Iovance Biotherapeutics (IOVA) Shares Issued (2016 - 2025)

Iovance Biotherapeutics has reported Shares Issued over the past 12 years, most recently at -$162.0 million for Q3 2025.

Quarterly results put Shares Issued at -$162.0 million for Q3 2025, down 440.91% from a year ago — trailing twelve months through Dec 2025 was $15000.0 (down 99.54% YoY), and the annual figure for FY2025 was $15000.0, down 99.54%.
Shares Issued for Q3 2025 was -$162.0 million at Iovance Biotherapeutics, down from $162.0 million in the prior quarter.
Over the last five years, Shares Issued for IOVA hit a ceiling of $349.4 million in Q2 2024 and a floor of -$394.0 million in Q4 2024.
Median Shares Issued over the past 3 years was $21.0 million (2023), compared with a mean of $30.5 million.
Peak annual rise in Shares Issued hit 13.95% in 2024, while the deepest fall reached 4925575.0% in 2024.
Iovance Biotherapeutics' Shares Issued stood at $8000.0 in 2023, then plummeted by 4925575.0% to -$394.0 million in 2024, then soared by 58.89% to -$162.0 million in 2025.
The last three reported values for Shares Issued were -$162.0 million (Q3 2025), $162.0 million (Q2 2025), and $15000.0 (Q1 2025) per Business Quant data.